Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0BHGIG
ADC Name
DAR4-ARC-ADC
Synonyms
Anti-hCLL-1 ARC-ADC DAR4
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Acute myeloid leukaemia [ICD11:2A60]
Investigative
Drug-to-Antibody Ratio
4
Structure
Antibody Name
Undisclosed
Antigen Name
Collectin-10 (COLEC10)
  Antigen Info 
Payload Name
Monomethyl auristatin F
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
NAD-based dinucleotide linker
  Linker Info 
Conjugate Type
MMAF was covalently attached to antibodies genetically fused with CD38 via ADP-ribosyl cyclase catalytic glutamate 226 (Glu226) residue, conjugating through a 2-Cl-araNAD group.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Effective Concentration (EC50) 
25
pM
U-937 cells
Adult acute monocytic leukemia
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 25.00 pM Positive CLL-1 expression (CLL-1+++/++)
Method Description
In vitro cytotoxicity of the anti-hCLL-1 ARC-ADCs was then evaluated using human AML cell lines U937 (CLL-1+) and KG1a (CLL-1-1).
In Vitro Model Adult acute monocytic leukemia U-937 cells CVCL_0007
References
Ref 1 Site-specific antibody-drug conjugates with variable drug-to-antibody-ratios for AML therapy. J Control Release. 2021 Aug 10;336:433-442. doi: 10.1016/j.jconrel.2021.06.041.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.